High-quality iPSC products and services for accelerated drug discovery
Induced pluripotent stem cells (iPSC)-based disease modelling has revolutionized the ways in which we explore the mechanisms of human diseases and develop therapies. While iPSCs offer an attractive and robust in vitro disease model for novel drug development, their genetic instability, heterogeneity, and quality control remain a matter of concern. At Syngene, we have successfully generated high quality iPSCs followed by extensive characterization to ensure quality of the final clones and their derivatives.
With our experience and expertise in this area, we provide solutions to generate feeder free and viral integration free iPSC clones meant for cellular assays and screening. We perform iPSC reprogramming, characterization, gene editing using CRISPR and advanced nucleases, differentiation of iPSCs into multiple lineages and in vitro assays using iPSC derivatives or primary cells. We also have expertise in CAR-T platform.
Our iPSC product offerings
- iPSC reprogramming – Integration free (Sendai, episomal); feeder free from healthy or diseased patients
-
Guaranteed high reprogramming efficiency
-
Well established SOPs to generate high quality iPSCs; experience in generating CAR-T, neuronal and cardiomyocyte lines
-
Extensive QC and CoA preparation for every batch to produce consistent results
-
Carefully monitored LN2 storage to ensure >80% cell viability upon thawing
-
Tie-ups with local hospitals for availability of diverse starting material for iPSC reprogramming
-
Well established donor network, including sample collection procedure
-
Extensive screening processes for each donor sample to ensure high sample quality
-
Availability of automated cell banking for systematic storage of donor samples